Lead Product(s): CTX-177
Therapeutic Area: Oncology Product Name: CTX-177
Highest Development Status: IND Enabling Product Type: Small molecule
Partner/Sponsor/Collaborator: Ono Pharmaceutical
Deal Size: $509.7 million Upfront Cash: Undisclosed
Deal Type: Collaboration December 15, 2020
Under the terms of the agreement, Chordia will grant exclusive rights to develop, manufacture and commercialize CTX-177 and other related compounds globally.